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gust 6, 2013.he aim of this study was to determine the role of suppressor of cytokine signaling 1 (SOCS1) in graft
arteriosclerosis (GA).Background GA, the major cause of late cardiac allograft failure, is initiated by immune-mediated endothelial activation resulting
in vascular inﬂammation and consequent neointima formation. SOCS1, a negative regulator of cytokine signaling, is
highly expressed in endothelial cells (ECs) and may prevent endothelial inﬂammatory responses and phenotypic
activation.Methods Clinical specimens of coronary arteries with GA, with atherosclerosis, or without disease were collected for
histological analysis. SOCS1 knockout or vascular endothelial SOCS1 (VESOCS1) transgenic mice were used in an
aorta transplant model of GA. Mouse aortic ECs were isolated for in vitro assays.Results Dramatic but speciﬁc reduction of endothelial SOCS1was observed in humanGA and atherosclerosis specimens, which
suggested the importance of SOCS1 in maintaining normal endothelial function. SOCS1 deletion in mice resulted in
basal EC dysfunction. After transplantation, SOCS1-deﬁcient aortic grafts augmented leukocyte recruitment and
neointima formation, whereas endothelial overexpression of SOCS1 diminished arterial rejection. Induction of
endothelial adhesion molecules in early stages of GA was suppressed by the VESOCS1 transgene, and this effect was
conﬁrmed in cultured aortic ECs. Moreover, VESOCS1 maintained better vascular function during GA progression.
Mechanistically, endothelial SOCS1, by modulating both basal and cytokine-induced expression of the adhesion
molecules platelet/endothelial cell adhesionmolecule-1, intercellular adhesionmolecule-1, and vascular cell adhesion
molecule-1, restrained leukocyte adhesion and transendothelial migration during inﬂammatory cell inﬁltration.Conclusions SOCS1 prevents GA progression by preserving endothelial function and attenuating cytokine-induced adhesion
molecule expression in vascular endothelium. (J Am Coll Cardiol 2014;63:21–9) ª 2014 by the American College
of Cardiology FoundationSee page 30Pathological vascular remodeling is the major cause of
cardiovascular diseases. A prototypical example of patholog-
ical vascular remodeling is graft arteriosclerosis (GA), also
referred to as cardiac allograft vasculopathy, which leads to
clinical failure of organ allografts after the ﬁrst year post-
transplantation (1,2). The development of GA arises from
the recruitment of acute inﬂammatory cells (e.g., macro-
phages) and subsequent alloantigen-responsive T cells on
recognition of graft endothelial cells (ECs). The localam in Vascular Biology and Therapeutics,
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3; revised manuscript received August 5, 2013,production of proinﬂammatory cytokines, in turn, drives
vascular smooth muscle cell migration and proliferation
within the neointima, leading to luminal obstruction and
allograft ischemia. The critical initiating events in this process
are EC activation and the consequent induction of endo-thelial adhesion molecules, including E-selectin, P-selectin,
intercellular adhesion molecule (ICAM)-1, vascular cell
adhesion molecule (VCAM)-1, and platelet/endothelial cell
adhesion molecule (PECAM)-1. The enhanced expression
of endothelial adhesion molecules provides an environment
for initial adhesion and subsequent migration of inﬂamma-
tory cells into the vessel wall. Leukocyte adhesion to activated
ECs is a sequential, multistep process consisting of tethering,
rolling, ﬁrm adhesion, and transmigration (3). Each adhesion
molecule has speciﬁc functions in the adhesion cascade of
inﬂammatory cell recruitment; selectins are associated with
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22cell rolling, ICAM-1 andVCAM-1
correlate to ﬁrm adhesion, and
PECAM-1 is responsible for
paracellular transmigration. The
major stimuli for induction of en-
dothelial adhesion molecules are
proinﬂammatory cytokines, which
typically include interleukin (IL)-6
and interferon (IFN)-g in GA.
Among IFN-g–induced ge-
nes, suppressor of cytokine sig-
naling 1 (SOCS1) is an attractive
candidate as a putative regulator
of GA pathogenesis. SOCS1,
a member of the SOCS family of
proteins, was ﬁrst identiﬁed as
a negative feedback inhibitor
of cytokine signaling. So far,SOCS1 has been implicated in the regulation of dozens of
cytokines, including IL-6 and IFN-g. It not only functions
as a powerful attenuator of JAK-STAT signaling, but also
has been shown to disrupt other inﬂammatory pathways by
regulating nuclear factor kB (4) and ASK1 degradation,
based on our previous work (5,6). In addition to those in vitro
studies, the physiological role of SOCS1 is extensively
established in immune function and tumor progression.
SOCS1 is abundantly expressed in the thymus and spleen
and is induced in all immune cells by a large panel of cyto-
kines and pathogens. SOCS1-deﬁcient mice die approxi-
mately 2 to 3 weeks post-natally because of overactive
inﬂammatory responses (7,8). On the other hand, SOCS1
overexpression in vivo results in a reduction of inﬂammatory
cytokines produced by inﬁltrating immunocytes (9,10). The
distinct role of SOCS1 in inﬂammation regulation is corre-
lated with several immunological diseases, such as multiple
sclerosis (11), inﬂammatory arthritis (12), and diabetes
(13,14). Additionally, SOCS1 functions as a tumor
suppressor in carcinogenesis. Decreased SOCS1 expression
in cancer cells and increased expression in stromal cells have
been observed in a variety of tumor samples. In clinical
practice, SOCS1 has been set up as a diagnostic biomarker of
tumors at both the transcriptional (15,16) and post-
translational levels (17,18). Although we have previously
dissected part of the SOCS1 signal transduction pathway
in cultured ECs (5,6), little is known about the pathophysi-
ological role of SOCS1 in the cardiovascular system. In the
present study, we investigated the role of SOCS1 in vascular
ECs within GA based on both analysis of clinical specimens
and experimental research in mouse models of disease.
Methods
An expanded Methods section is provided in an Online
Appendix that includes descriptions of clinical speci-
mens, generation of SOCS1 transgenic mice, mouse
aortic transplantation model, graft analyses, cell culture,immunoprecipitation and immunoblotting, leukocyte-endo-
thelial adhesion and transmigration assays, statistical analyses,
and Online Figures S1 to S6.Results
Loss of endothelial SOCS1 expression correlates with
arterial disease in clinical samples. SOCS1 expression in
human vascular cells has been described in several in vitro
studies. To determine the expression pattern of SOCS1 in
clinical specimens of vascular disease, human coronary
arteries with GA from transplanted hearts and with
atherosclerotic plaque, or no disease from nontransplanted
hearts, were collected for histological examination. SOCS1
was abundantly expressed in nondiseased arteries, whereas it
was dramatically reduced in diseased arteries, especially
within the luminal endothelial layer identiﬁed by PECAM-1
staining (Figs. 1A and 1B, with quantiﬁcation in 1B).
However, no signiﬁcant differences were detected at the
messenger ribonucleic acid (mRNA) level between healthy
and diseased arteries (Online Fig. S1), suggesting dimin-
ished SOCS1 protein synthesis. Histological analysis also
demonstrated obvious intimal expansion with plentiful
leukocyte inﬁltration, as shown by CD45 immunostaining
of diseased arteries (Figs. 1C and 1D, with quantiﬁcation
in Fig. 1D). Therefore, to further determine a link between
endothelial SOCS1 expression and vascular inﬂammation,
we assessed the adhesion molecules and the markers of EC
activation, ICAM-1 and VCAM-1, by immunoﬂuores-
cence. In contrast to the pattern for SOCS1, expression
levels of ICAM-1 and VCAM-1 were markedly enhanced,
whereas that of PECAM1 was slightly increased in the
endothelium of diseased arteries compared with nondiseased
controls (Fig. 1E). These results suggest a protective role of
SOCS1 in pathological vascular remodeling by preventing
endothelial activation and vascular inﬂammation.
SOCS1 deletion in mice exacerbates GA and EC
dysfunction. To further investigate the function of SOCS1
in vessel wall cells under pathological conditions, we used
a mouse aorta transplantation model of GA that we estab-
lished in a previous study (19,20). Brieﬂy, a segment of male
donor thoracic aorta is interposed into the abdominal aorta of
a female recipient of the same background strain. The host
then mounts an alloimmune response against the male-
speciﬁc H-Y minor histocompatibility antigen expressed by
the graft in which leukocyte-derived proinﬂammatory
cytokines induce endothelial activation and drive graft
neointima formation (19–22). Because SOCS1 knockout
(SOCS1-KO) mice die perinatally, as a result of over-
production of inﬂammatory cytokines, we used SOCS1-KO
mice from an IFN-g–deﬁcient background in which the
mice survive normally (23). Transplantation of the IFN-g–
KO male C57BL/6 (B6) to female B6 aorta induced GA, as
characterized by graft inﬁltration with leukocytes and neo-
intima formation (Figs. 2A and 2B, with quantiﬁcation in
Fig. 2B). Strikingly, SOCS1/IFN-g–KO male B6 donor
Figure 1 Loss of SOCS1 Expression Correlates With Clinical Pathological Vascular Remodeling
Human coronary artery specimens with graft arteriosclerosis (GA) from chronically rejecting heart allografts and with atherosclerotic plaques or no disease from nontransplanted
hearts were collected. (A, B)Dramatically decreased endothelial suppressor of cytokine signaling 1 (SOCS1) expression in diseased vessel wall. Endothelial SOCS1 expression is
demonstrated by immunoﬂuorescence analysis of artery crosssections stained for SOCS1 and the endothelial marker platelet/endothelial cell adhesion molecule (PECAM)-1 with
4’,6-diamidino-2-phenylindole (DAPI) labeling of nuclei. Representative images are shown in A, and quantiﬁcations are in B. Bar ¼ 50 mm. (C, D) Inﬂammatory cell and vascular
smooth muscle cell accumulation are demonstrated by immunoﬂuorescence analysis of artery cross sections stained for the leukocyte commonmarker CD45 and smooth muscle
a-actin with DAPI labeling of nuclei. Representative images are shown with quantiﬁcation in the histogram. Bar¼ 50 mm. (E) Induction of endothelial adhesion molecules has the
opposite expression pattern as endothelial SOCS1. Representative histological analysis of artery cross sections stained with intercellular adhesion molecule (ICAM)-1 or vascular
cell adhesion molecule (VECAM)-1 and PECAM-1 antibodies. Immunoﬂuorescence sections were counterstained with DAPI. Bar ¼ 50 mm. (B, D) Data are mean  SEM from
independent clinical specimens of varying numbers per group as indicated; **p < 0.01, ***p < 0.001, 1-way ANOVA followed by the Bonferroni post-hoc test.
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23grafts to female B6 recipients generated signiﬁcantly
larger neointima that contained more CD45-positive inﬁl-
trating leukocytes, resulting in lumen loss compared with the
IFN-g–KO donor group (Figs. 2A and 2B, with quantiﬁca-
tion in Fig. 2B).
Because EC activation and dysfunction has been impli-
cated as the early step for arteriosclerosis progression, we
investigated whether SOCS1 deﬁciency might affect endo-
thelial function of the vessel wall. To this end, aortas from
IFN-g–KO or SOCS1/IFN-g–KO mice were isolated
for vessel function assays. Vascular reactivity of isolatedaortic rings was determined by examining their responses
to vasoconstrictor phenylephrine (PE), endothelium-
dependent vasodilator acetylcholine (Ach), and the nitric
oxide synthase inhibitor L-nitroarginine methyl ester
(L-NAME). Compared with IFN-g–KO aortas, those from
SOCS1/IFN-g–KO mice showed increased constriction in
response to PE but reduced relaxation in response to Ach
(Online Fig. S2). These results are consistent with our clinical
observations discussed previously and support a role for
SOCS1 in preventing GA pathogenesis in which SOCS1-
regulated EC function may be a potential mechanism.
Figure 2 SOCS1 Deletion Enhances GA in Mice
Aortas from interferon gamma knockout (IFN-g–KO) and SOCS1/IFN-g–KO male B6 donors were transplanted to female B6 recipients, and the allografts were harvested 2 weeks
post-operatively. (A) Histological analysis of artery grafts were carried out by EVG staining and immunostaining by anti-SMA and anti-CD45 antibodies with DAPI labeling of
nuclei. Representative photomicrographs are shown. Arrowheads mark the internal elastic lamina to delineate the intima from medium. Bar ¼ 50 mm. (B) Morphometric
assessment of artery graft intima, media, lumen, and vessel areas and quantiﬁcation of CD45þ cells inﬁltrating the intima and medium of each artery graft cross section. Data
are mean  SEM from 6 mice per group; *p < 0.05, **p < 0.001, unpaired t test. EVG ¼ Elastic Van Gieson; other abbreviations as in Figure 1.
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24Vascular endothelial SOCS1 overexpression in mice
inhibits GA. The preceding conclusions led us to hypoth-
esize that SOCS1 may function as a negative regulator of
endothelial activation during GA. To clarify this issue, we
generated a VE-cadherin promoter-driven SOCS1 trans-
genic mouse (VESOCS1) (Online Fig. S3A) and back-
crossed it onto the B6 background for more than 10
generations. EC-speciﬁc expression of SOCS1 was deter-
mined at bothmRNA and protein levels (Online Figs. S3B to
S3D). Nontransgenic wild-type (WT) littermates and
VESOCS1 male mice were used as aorta donors in the GA
model described earlier. Donor grafts were harvested at 2
weeks after transplantation for histological analysis and
morphometric assessment. Aorta grafts overexpressing
SOCS1 generated signiﬁcantly less neointima and contained
fewer CD45þ inﬂammatory cells than the WT vessels
(Figs. 3A and 3B). To assess the effects on inﬂammation-
induced EC signaling, IL-6 and IFN-g were selected for
evaluation as they represent major proinﬂammatory cyto-
kines produced in GA (24–28). Real-time quantitative
polymerase chain reaction results showed no signiﬁcant
differences between cytokine production of the WT group
and that of the VESOCS1 group (Online Fig. S4). In
contrast, there was decreased cytokine signaling as assessed
by immunostaining for phosphorylated JAK2 and phos-
phorylated STAT3 in aortas overexpressing SOCS1 at
3 days post-operatively (Figs. 3C and 3D). The expressionof these activated signaling molecules colocalized with
PECAM-1, demonstrating events within the graft ECs.
Because JAK-STAT signaling is one of the major pathways
in proinﬂammatory cytokine-mediated EC activation, these
results provide clues to the exploration of the effects of
SOCS1 in GA progression.
SOCS1 is a negative regulator of endothelial activation
in GA. To further determine the function of SOCS1 in
GA, we examined samples for markers of EC activation
early after transplantation of WT and VESOCS1 grafts
prior to discernable neointima formation. At 3 days post-
operatively, real-time quantitative polymerase chain reaction
revealed decreased mRNA expression of the inducible
endothelial adhesion molecules ICAM-1 and VCAM-1
(but not PECAM-1) in VESOCS1 aortas compared to
that in the WT group (Fig. 4A). Immunostaining conﬁrmed
an inhibitory effect of SOCS1 on the expression of ICAM-1
and VCAM-1 and also of PECAM-1 in the graft endothe-
lium (Fig. 4B). Correspondingly, we observed that numbers of
inﬁltrating leukocytes were decreased in VESOCS1 grafts
compared with those in theWT group (Figs. 4C and 4D). On
the other hand, vessel function assays revealed reduced
constriction of VESOCS1 graft in response to PE but
enhanced relaxation in response to Ach when compared with
B6 controls (Online Fig. S5). Taken together, these results
demonstrate the direct role of SOCS1 in preventing endo-
thelial activation and dysfunction during GA formation.
Figure 3 EC-Speciﬁc Overexpression of SOCS1 Inhibits GA in Mice
Aortas from nontransgenic littermate wild type (WT) and vascular endothelial suppressor of cytokine signaling 1 (VESOCS1) male B6 mice were transplanted to female B6
recipients and the allografts were harvested 2 weeks or 3 days post-operatively. (A) Histological analysis of 2-week artery grafts by EVG and immunostaining by anti-SMA and
anti-CD45 antibodies with DAPI labeling of nuclei. Representative photomicrographs are shown. Arrowheadsmark the internal elastic lamina to delineate the intima from media.
Bar ¼ 50 mm. (B) Morphometric assessment of artery graft intima, media, lumen, and vessel areas and quantiﬁcation of CD45þ cells inﬁltrating the intima and media of each
artery graft. (C) Endothelial cell (EC)-speciﬁc expression of SOCS1 inhibited proinﬂammatory cytokine-induced Janus kinase (JAK)2 and STAT3 activation in vessel grafts. Cross
sections of WT or VESOCS1 grafts at day 3 were coimmunostained with antibodies to phosphorylated (p)-JAK2 or p-STAT3 and the EC marker PECAM-1 with DAPI labeling of
nuclei. Representative images are shown. Bar ¼ 50 mm. (D) Quantiﬁcation of the endothelial signaling data in C. Data are mean  SEM from 5 to 6 mice per group; *p < 0.05,
**p < 0.001, unpaired t test. Abbreviations as in Figure 1.
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25SOCS1 overexpression restrains expression of adhesion
molecules and leukocyte-endothelial adhesion and trans-
migration. To deﬁne how SOCS1 mediates gene expres-
sion of PECAM-1, ICAM-1, and VCAM-1 in vascular
EC, we further examined the effects of the SOCS1 trans-
gene in isolated primary mouse aortic EC. We observed that
the basal level of PECAM-1, which is both a major scaffold
protein and also an adhesion molecule of ECs, is clearly
suppressed in the presence of the SOCS1 transgene
(Fig. 5A). Consistent with in vivo ﬁndings, PECAM-1
mRNA was not altered by SOCS1 transgene expression
(data not shown), suggesting that SOCS1 may regulatePECAM-1 expression at a post-translational level. We
investigated whether SOCS1 mediates PECAM-1 protea-
somal degradation as reported previously (29). In aortic ECs
from VESOCS1 animals, the low expression level of
PECAM-1 was strongly reversed by the presence of
MG132, a panproteasome inhibitor (Fig. 5A). Moreover,
associations between SOCS1 and PECAM-1 could be
detected by a coimmunoprecipitation assay with anti-
PECAM-1 followed by Western blotting for SOCS1 in
the same primary cells (Fig. 5B). Therefore, these results
demonstrate that SOCS1 binds PECAM-1 and mediates its
proteasomal degradation.
Figure 4 EC-Speciﬁc Expression of SOCS1 Inhibits Endothelial AdhesionMolecule Induction and Corresponding Leukocytic Inﬁltration in GA
Aortas from nontransgenic littermate WT and VESOCS1 male B6 mice were transplanted to female B6 recipients and the allografts were harvested 3 days post-operatively.
(A)Transcripts for theendothelial adhesionmolecules, ICAM-1andVCAM-1, fromWTandVESOCS1graftswerequantiﬁedbyquantitativepolymerasechain reactionandnormalized to
HPRT. (B) Induction of endothelial adhesion molecules was also determined by immunostaining with antibodies to ICAM-1 or VCAM-1 and PECAM-1 with DAPI labeling of nuclei.
Representative images are shown.Bar¼50mm. (C) Leukocyte inﬁltrationwasdetermined by immunostainingwith antibodies to the pan-leukocytemarker, CD45, or themacrophage
marker,Mac3, and endotheliummarker, PECAM-1. Representative images are shown.Bar¼50mm. (D)Quantiﬁcation of the number of leukocytes inC. Data aremeanSEM from4
to 5 mice per group; *p < 0.05, **p < 0.001, unpaired t test. HPRT ¼ hypoxanthine-guanine phosphoribosyltransferase; other abbreviations as in Figures 1 and 3.
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26In contrast to PECAM-1, we observed that both the
mRNA (not shown) and the protein (Fig. 5C) levels of
ICAM-1 and VCAM-1 were up-regulated by IL-6 and
IFN-g, and this regulation was attenuated by the SOCS1
transgene (Fig. 5C). Because both IL-6 and IFN-g use
JAK-STAT’s signaling pathways to induce gene expression
of proinﬂammatory molecules, we examined the signaling
responses in aortic ECs. Primary cultured aortic ECs weretreated with mouse IL-6 or IFN-g, and activation of
their downstream signaling mediators was determined by
Western blotting with phospho-speciﬁc antibodies. IL-6
induced activation of JAK2 and STAT3, and the SOCS1
transgene reduced IL-6–activated JAK2-STAT3 signaling
(Fig. 5D). IFN-g induced activation of JAK1/2 and
STAT1/3 in aortic ECs, and IFN-g–activated signaling
was attenuated by the SOCS1 transgene in EC (Fig. 5C).
Figure 5 EC-Speciﬁc Expression of SOCS1 Weakens Proinﬂammatory Cytokine Responses in Primary Cultured Aortic EC
(A) SOCS1 promotes proteasomal degradation of PECAM-1. Primary cultured WT and VESOCS1 mouse aortic ECs were treated with the pan-proteasome inhibitor MG132 for the
indicated times. Expression of PECAM-1 and SOCS1 was determined by Western blotting with the respective antibodies. PECAM-1 expression was quantiﬁed with untreated WT
normalized at a value of 1.0. (B) SOCS1 associated with PECAM-1 in mouse aortic EC. Primary cultured WT and VESOCS1 mouse aortic ECs were lysed in radioimmuno-
precipitation assay buffer. Association of SOCS1 with PECAM-1 was determined by a coimmunoprecipitation assay with anti-SOCS1, followed by Western blotting with
anti–PECAM-1 or anti-SOCS1. (C) Isolated WT and VESOCS1 mouse aortic ECs were cultured in serum-free medium for 24 h, followed by treatment with mouse IFN-g (10 ng/ml)
or IL-6 (10 ng/ml) for the indicated times. Induction of endothelial adhesion molecules was determined. VCAM-1 and ICAM-1 expression levels were quantiﬁed with untreated WT
normalized to a value of 1.0. (D, E) Isolated WT and VESOCS1 mouse aortic ECs were cultured in serum-free medium for 24 h, followed by treatment with mouse IFN-g (10 ng/ml)
or IL-6 (10 ng/ml) for the indicated times. Phosphorylation of JAK1, JAK2, STAT1, and STAT3 and total proteins was determined by Western blotting with the respective
antibodies. SOCS1 and b-actin were also determined. All experiments in A to E were repeated 3 times. Abbreviations as in Figures 1 and 3.
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27These effects of SOCS1 on JAK-STAT activation are
consistent with the in vivo observations (Fig. 3). In
summary, these results demonstrate that SOCS1 speciﬁ-
cally inhibits proinﬂammatory cytokine responses in
vascular EC.
To correlate the role of SOCS1 in proinﬂammatory
cytokine signaling to its effect on vascular inﬂammation, we
determined the effects of SOCS1 overexpression by using
in vitro assays of leukocyte-endothelial adhesion and
transmigration, 2 critical steps involved in inﬂammatory
cell recruitment (30,31). In an adhesion assay using
ﬂuorescently pre-labeled mouse monocytes seeded ontoconﬂuent, primary cultured aortic EC, SOCS1 over-
expression had no effect on monocyte attachment to resting
ECs but prevented proinﬂammatory cytokine-mediated
monocyte attachment compared with the WT group
(Online Figs. S6A and S6B). Similarly, an inhibitory effect
of the SOCS1 transgene on monocyte transmigration
across cytokine-activated ECs was observed in a trans-
endothelial migration assay (30) (Online Figs. S6C and
S6D). These data suggest that SOCS1 speciﬁcally regulates
proinﬂammatory cytokine-dependent functions in vascular
ECs that are relevant for leukocyte trafﬁcking and devel-
opment of GA.
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28Discussion
In the present study, we investigated the role of SOCS1 in
GA by assessing clinical specimens and using a mouse aorta
transplantation model, across the H-Y–dependent minor
histocompatibility antigen barrier, which closely mimics GA
progression as we have previously described (20). Here we
demonstrate that SOCS1 is highly expressed in the luminal
endothelium of nondiseased human coronary arteries,
whereas its expression is decreased in ECs of chronically
rejecting heart grafts and of those of atherosclerotic plaques.
Such dramatic loss of expression accompanied by abundant
immune cell inﬁltration in the pathologically remodeled
vessel wall suggests a regulatory role for SOCS1 in GA
pathogenesis. Clinical observation is supported by enhanced
intimal expansion and increased leukocyte inﬁltration as
well as EC dysfunction in SOCS1-deﬁcient murine allo-
grafts. Because endothelial activation initiates leukocytic
inﬁltration and neointima formation, a critical role for
SOCS1, speciﬁcally in the endothelium of transplanted
aortas, is implied. To this end, transgenic mice over-
expressing SOCS1 in vascular endothelial cells were
generated. Grafts from VESOCS1 mice exhibit dramati-
cally decreased endothelial activation, leukocyte inﬁltration,
and neointima formation. ECs from VESOCS1 grafts also
blunt proinﬂammatory cytokine signaling and induction of
adhesion molecules. This mirrors the ﬁnding of decreased
endogenous SOCS1 and enhanced adhesion molecule
expression in the endothelium of clinical GA specimens.
Mechanistically, we show that SOCS1 overexpression in
ECs signiﬁcantly reduces IL-6– and IFN-g–induced JAK2-
STAT1/3 signaling and leukocyte-endothelial adhesion and
transmigration. Furthermore, we show that SOCS1 directly
binds to PECAM-1 and interrupts PECAM-1 stability.
We conclude that endothelial SOSC1 prevents GA by
down-regulating proinﬂammatory cytokine-induced EC
activation and subsequent leukocyte inﬁltration.
Negative role of SOCS1 in endothelial inﬂammation.
GA progression depends closely on inﬂammation, the
important ampliﬁcation mechanism of innate and adaptive
immunity. Inﬁltration of immune cells into the vessel wall,
including neutrophils, macrophages, and T cells, requires
vascular endothelial activation.Characterized by the induction
of adhesion molecules, endothelial activation results in
adherence of immune cells from the circulation onto endo-
thelium, followed by transendothelialmigration into the artery
wall. In the present study, clinical analysis suggests a special
inhibitory role of SOCS1on endothelial sensing and responses
during vascular rejection. This observation supports our
further investigations into the role of SOCS1 in maintaining
EChomeostasis. In addition to preservingEC vessel function,
we also ﬁnd that SOCS1 overexpression in vascular EC
inhibits the induction of endothelial adhesion molecules by
proinﬂammatory cytokines. To this extent, our results reveal
an important role for SOCS1 as a negative regulator of
endothelial activation and subsequent arterial inﬂammation.Dual regulatory mechanisms of endothelial adhesion
molecule expression by SOCS1. Most studies of the
SOCS family have focused on the immune system,
including the regulation of cytokine production by immune
cells in vascular diseases. To determine the effect of endo-
thelial SOCS1 overexpression on inﬂammatory cytokine
generation, we assessed the levels of IL-6 and IFN-g
transcripts typically expressed in GA lesions. No signiﬁcant
differences between the levels of WT and those of the
VESOCS1 groups were detected. This suggests that the
responses of SOCS1-expressing ECs are critical to under-
standing GA progression and need to be elucidated.
Up-regulation of adhesion molecule expression generally
involves transcriptional mechanisms. In addition to nuclear
factor kB, STAT family members are major transcriptional
factors controlling the expression of inducible adhesion
molecules, such as ICAM-1 and VCAM-1, and are
canonical signaling mediators for many inﬂammatory
stimuli (32,33). Upon binding of different proinﬂammatory
cytokines to their receptors, intracellular activation of the
Janus kinases JAK1 and JAK2 is initiated, which leads to
autophosphorylation and downstream STAT recruitment
and phosphorylation. Activated STATs subsequently form
homodimers and translocate to the nucleus to launch target
gene expression. In our present study, inhibition of proin-
ﬂammatory cytokine-induced JAK-STAT signaling by
endothelial SOCS1 is identiﬁed as its molecular function on
endothelial activation. Of note, IL-6 activates STAT1 while
IFN-g induces broader STAT activation in vascular ECs.
More interestingly, our ﬁndings illustrate a novel mecha-
nism of SOCS1’s effects on endothelial adhesion molecule
expression, in addition to transcription. We identify the fact
that SOCS1 interacts directly with PECAM-1 to enhance
its degradation. The association of PECAM-1 down-
regulation and its phosphorylation in activated EC has been
previously reported (29) but little is known regarding the
mechanisms. Here we demonstrate that SOCS1 is a potent
negative mediator in this process.
Pathophysiological function of SOCS1 in pathological
vascular remodeling. As a major member of the SOCS
family, SOCS1 has received the most attention as a critical
negative regulator of immune cells. In pathological vascular
remodeling, inﬁltration of immune cells is the major source
of proinﬂammatory cytokines that activate vascular ECs and
vascular smooth muscle cells as well as other vessel wall cells.
In response to proinﬂammatory cytokines, SOCS1 is
induced in these inﬂammatory inﬁltrating cells and nega-
tively regulates the generation of these cytokines (34). Based
on both clinical and experimental data, the present study
reveals a critical function of SOCS1 in vascular EC activa-
tion, dysfunction, and homeostasis. Our results shed light on
the role of SOCS1 in vessel wall cells, which expands the
understanding of the SOCS family beyond their traditional
role in the immune system. To our surprise, endothelial
SOCS1 expression is inhibited and not induced by the
occurrence of both clinical GA and atherosclerosis. The fact
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29that SOCS1 mRNA was not reduced in these specimens
suggests that protein degradation may represent a novel
regulation mechanism for SOCS1 expression. However, we
cannot exclude the expression of endogenous SOCS1 tran-
scripts in vessel wall cell types other than ECs, such as
inﬁltrating leukocytes. Recent other studies report that
SOCS1 expressed in smooth muscle cells is a key regulator
of vascular cell responses in atherosclerosis (35). Our
observation is also consistent for SOCS1 induction in the
underlying neointima and shoulder regions of plaques
beyond endothelium (Fig. 1A). Herewith, SOCS1 is an
important regulator in maintaining normal function of the
vasculature in pathological vascular remodeling. Modulation
of endothelial SOCS1 expression and activity may represent
a novel strategy for the treatment of cardiovascular diseases,
such as GA and atherosclerosis.
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APPENDIX
For an expanded methods section and supplemental ﬁgures, please see the
online version of this article.
